A new drug called VUITY™ (pilocarpine hydrochloride ophthalmic solution) has recently gained attention as an eye drop that can improve near (close up) vision in individuals over 40. It does not, however, change the condition of the retina. The drug, made by Allergan, works as advertised, but it should not be expected to treat age-related […]
Apellis Pharmaceuticals has announced long term results from their Phase 3 DERBY and OAKS clinical studies, testing the efficacy and safety of APL-2 (now called intravitreal pegcetacoplan), as a treatment for geographic atrophy (GA). GA is also known as advanced dry age-related macular degeneration. In an analysis conducted at month 18 of the clinical studies, treatment […]
The FDA has approved Genentech’s Vabysmo (first announced here as faricimab), the only injectable eye medicine approved simultaneously in the U.S. for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo will be administered using flexible dosing regimens based on patient need. The medication targets and inhibits two disease pathways by neutralizing angiopoietin-2 […]
Researchers at Kaiser Permanente Washington have found strong evidence that cataract surgery can lower the risk of developing dementia for up to 10 years in senior adults. The news was reported in the December 6, 2021 issue of JAMA Internal Medicine. The Adult Changes in Thought (ACT) study of more than 5,000 senior adults showed […]
Prevent Blindness has launched its first-ever Geographic Atrophy (GA) Awareness Week from December 6-12, 2021. GA is an advanced form of dry age-related macular degeneration (commonly referred to as AMD) which leads to vision loss in the center of one’s vision. Geographic atrophy results in areas of damaged tissue causing central blind spots. It is […]